The neutrophil to lymphocyte ratio has a high negative predictive value for pathologic complete response in locally advanced breast cancer patients receiving neoadjuvant chemotherapy

Asian Pacific Journal of Cancer Prevention

Volumn 15, Issue 18, 2014, Pages 7737-7740

  Eryilmaz, Melek Karakurt ^a   Mutlu, Hasan ^a   Salim, Derya Kivrak ^a   Musri, Fatma Yalcin ^a   Tural, Deniz ^a   Coskun, Hasan Senol ^a  

^a AKDENIZ UNIVERSITY   (Turkey)

Author keywords

Breast cancer; Neoadjuvant chemotherapy; Neutrophil to lymphocyte ratio; Pathologic complete response

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADJUVANT THERAPY; BREAST NEOPLASMS; CANCER GRADING; CANCER STAGING; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; FEMALE; FOLLOW UP; HUMAN; LYMPHOCYTE; METABOLISM; MIDDLE AGED; NEUTROPHIL; PATHOLOGY; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; REMISSION; RETROSPECTIVE STUDY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHOCYTES; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM GRADING; NEOPLASM STAGING; NEUTROPHILS; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; ROC CURVE;

EID: 84908032509     PISSN: 15137368     EISSN: None     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.18.7737     Document Type: Article

References (30)

1. Aliustaoglu M, Bilici A, Seker M, et al (2010). The association of pre-treatment peripheral blood markers with survival in patients with pancreatic cancer. Hepatogastroenterology, 57, 640-5.
2. Azab B, Bhatt V, Phookhan J, et al (2012). Usefulness of the neutrophil-to-lymphocyte ratio in predicting short-and long-term mortality in breast cancer patients. Ann Surg Oncol, 19, 217-24.
3. Bear HD, Anderson S, Brown A, et al (2003). The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol, 21, 4165-74.
4. Bonadonna G, Veronesi U, Brambilla C, et al (1990). Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more. J Natl Cancer Inst, 82, 1539-45.
5. Buzdar AU, Ibrahim NK, Francis D, et al (2005). Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol, 23, 3676-85.
6. Cocquyt VF, Blondeel PN, Depypere HT, et al (2003) Different responses to preoperative chemotherapy for invasive lobular and invasive ductal breast carcinoma. Eur J Surg Oncol, 29, 361-67.
7. Colleoni M, Viale G, Zahrieh D, et al (2004). Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment. Clin Cancer Res, 10, 6622-8.
8. Cortazar P, Zhang L, Untch M, et al (2014). Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet, 13, 62422-8.
9. Coussens LM, Werb Z (2002). Inflammation and cancer. Nature, 420, 860-67.
10. Cristofanilli M, Gonzalez-Angulo A, Sneige N, et al (2005). Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes. J Clin Oncol, 23, 41-8.
11. Dou X, Wang RB, Yan HJ, et al (2013). Circulating lymphocytes as predictors of sensitivity to preoperative chemoradiotherapy in rectal cancer cases. Asian Pac J Cancer Prev, 14, 3881-5.
12. Fisher B, Brown A, Mamounas E, et al (1997). Effect of preopera tive chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol, 15, 2483-93.
13. Fogar P, Sperti C, Basso D, et al (2006). Decreased total lymphocyte counts in pancreatic cancer: an index of adverse outcome. Pancreas, 32, 22-8.
14. Fox P, Hudson M, Brown C, et al (2013). Markers of systemic inflammation predict survival in patients with advanced renal cell cancer. Br J Cancer, 109, 147-53.
15. Hennessy BT, Hortobagyi GN, Rouzier R, et al (2005). Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy. J Clin Oncol, 23, 9304-11.
16. Jung MR, Park YK, Jeong O, et al (2011). Elevated preoperative neutrophil to lymphocyte ratio predicts poor survival following resection in late stagegastric cancer. J Surg Oncol, 104, 504-10.
17. Kaufmann M, von Minckwitz G, Mamounas EP, et al (2012). Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer. Ann Surg Oncol, 19, 1508-16.
18. Kaya V, Yildirim M, Demirpence O, et al (2013). Prognostic significance of basic laboratory methods in non-small-cell-lung cancer. Asian Pac J Cancer Prev, 14, 5473-76.
19. Kim KI, Lee KH, Kim TR, et al (2014). Ki-67 as a predictor of response to neoadjuvant chemotherapy in breast cancer patients. J Breast Cancer, 17, 40-6.
20. Lv M, Li B, Li Y, et al (2011). Predictive role of molecular subtypes in response to neoadjuvant chemotherapy in breast cancer patients in Northeast China. Asian Pac J Cancer Prev, 12, 2411-7.
21. Noh H, Eomm M, Han A (2013). Usefulness of pretreatment neutrophil to lymphocyte ratio in predicting disease-specific survival in breast cancer patients. J Breast Cancer, 16, 55-9.
22. Ownby HE, Roi LD, Isenberg RR, et al (1983). Peripheral lymphocyte and eosinophil counts as indicators of prognosis in primary breast cancer. Cancer, 52, 126-30.
23. Ozdemir Y, Akin ML, Sucullu I, et al (2014). Pretreatment neutrophil/lymphocyte ratio as a prognostic aid in colorectal cancer. Asian Pac J Cancer Prev, 15, 2647-50.
24. Rastogi P, Anderson SJ, Bear HD, et al (2008). Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol, 26, 778-85.
25. Ray-Coquard I, Cropet C, Van Glabbeke M, et al (2009). European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas. Cancer Res, 69, 5383-91.
26. Schmidt H, Suciu S, Punt CJ, et al (2007). Pretreatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with American Joint Committee on Cancer Stage IV Melanoma: results of the EORTC 18951 Biochemotherapy Trial. J Clin Oncol, 25, 1562-69.
27. Sinacki M, Badzio A, Welnicka-Jaskiewicz M, et al (2011). Pattern of care in locally advanced breast cancer: focus on local therapy. Breast, 20, 145-50.
28. Strieter RM, Burdick MD, Mestas J, et al (2006). Cancer CXC chemokine networks and tumour angiogenesis. Eur J Cancer, 42, 768-78.
29. Templeton AJ, Ace O, McNamara MG, et al (2014). Prognostic role of platelet to lymphocyte ratio in solid tumors: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev, 23, 1204-12.
30. Unal D, Eroglu C, Kurtul N, et al (2013). Are neutrophil/lymphocyte and platelet/lymphocyte rates in patients with non-small cell lung cancer associated with treatment response and prognosis? Asian Pac J Cancer Prev, 14, 5237-42.